13F filer · CIK 882095
GILEAD SCIENCES, INC.
FOSTER CITY, CA · filing since Q4 2024 · last filing Nov 6, 2026
Reported value
$1.5B
$-184.9M vs prior
Positions
5
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%
Biggest buys vs Q2 2026
No new or increased positions this quarter.
Biggest sells vs Q2 2026
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Arcus Biosciences Inc.COM | 31,424,760 | $811.7M | 55.45% |
| 2 | Lakefront BiotherapeuticsSPON ADR | 16,707,477 | $501.3M | 34.24% |
| 3 | Assembly Biosciences Inc.COM NEW | 4,977,089 | $116.9M | 7.99% |
| 4 | Kyverna Therapeutics Inc.COM | 4,126,119 | $28.1M | 1.92% |
| 5 | Xilio Therapeutics Inc.COM | 650,389 | $5.9M | 0.40% |